Enhancement of chemosensitivity by simultaneously silencing of Mcl-1 and Survivin genes using small interfering RNA in human myelomonocytic leukaemia

References

• Löwenberg B, Rowe JM. Introduction to the review series on advances in acute myeloid leukemia (AML). Blood. 2016;127:1.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130.
   PubMed Web of Science ®Google Scholar
• Kupsa T, Milos Horacek J, Jebavy L. The role of cytokines in acute myeloid leukemia: a systematic review. Biomed Pap. 2012;156:291–301.
   PubMed Web of Science ®Google Scholar
• Frézard F, Garnier-Suillerot A. Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature. Biochim Biophys Acta. 1998;1389:13–22.
   PubMed Web of Science ®Google Scholar
• Rabbani A, Finn RM, Ausio J. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays. 2005;27:50–56.
   PubMed Web of Science ®Google Scholar
• Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist. 2009;14:240–252.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Delord J-P, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324–1334.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Shir Jang S, et al. Mechanisms of immune system activation in mammalians by small interfering RNA (siRNA). Artif Cells Nanomed Biotechnol. 2016;44:1589–1596.
   PubMed Web of Science ®Google Scholar
• Prabha S, Vyas R, Gupta N, et al. RNA interference technology with emphasis on delivery vehicles—prospects and limitations. Artif Cells Nanomed Biotechnol. 2016;44:1391–1399.
   PubMed Web of Science ®Google Scholar
• Shajari N, Davudian S, Kazemi T, et al. Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression. Artif Cells Nanomed Biotechnol. 2017 [cited Sep 11]; [10 p.]. DOI:10.1080/21691401.2017.1374284
   Web of Science ®Google Scholar
• Musavi Shenas SMH, Mansoori B, Mohammadi A, et al. SiRNA-mediated silencing of Snail-1 induces apoptosis and alters micro RNA expression in human urinary bladder cancer cell line. Artif Cells Nanomed Biotechnol. 2017;45:969–974.
   PubMed Web of Science ®Google Scholar
• Cai M, Chen Q, Chen C, et al. Activation of triggering receptor expressed on myeloid cells-1 protects monocyte from apoptosis through regulation of myeloid cell leukemia-1. Anesthesiology. 2013;118:1140–1149.
   PubMed Web of Science ®Google Scholar
• Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2009;66:1326–1336.
   PubMed Web of Science ®Google Scholar
• Bose P, Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk Res Rep. 2013;2:12–14.
   PubMedGoogle Scholar
• Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–1132.
   PubMed Web of Science ®Google Scholar
• Ghanbari P, Mohseni M, Tabasinezhad M, et al. Inhibition of Survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol. 2014;174:667–681.
   PubMed Web of Science ®Google Scholar
• Hosseini S, Hashemzadeh S, Estiar MA, et al. Expression analysis of aurora-C and Survivin, two testis-specific genes, in patients with colorectal cancer. Clin Lab. 2015;61(5–6):475–480.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–446.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Grant S, Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev. 2010;36:142–150.
   PubMed Web of Science ®Google Scholar
• Åström M, Bodin L, Nilsson I, et al. Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer. 2000;82:1387.
   PubMed Web of Science ®Google Scholar
• Shore GC, Warr MR. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med. 2008;8:138–147.
   PubMed Web of Science ®Google Scholar
• Chetoui N, Sylla K, Gagnon-Houde J-V, et al. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res. 2008;6:42–52.
   PubMed Web of Science ®Google Scholar
• Wei S-H, Dong K, Lin F, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 2008;62:1055–1064.
   PubMed Web of Science ®Google Scholar
• Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat. 2002;5:65–72.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5:1087–1098.
   PubMed Web of Science ®Google Scholar
• Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111:196–203.
   PubMed Web of Science ®Google Scholar
• Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett. 2007;252:9–18.
   PubMed Web of Science ®Google Scholar
• Zaffaroni N, Pannati M, Diadone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med. 2005;9:360–372.
   PubMed Web of Science ®Google Scholar
• Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep. 2012;14:120–128.
   PubMed Web of Science ®Google Scholar
• Rodel F, Sprenger T, Kaina B, et al. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem. 2012;19:3679–3688.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Shirjang S, et al. HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. Cell Cycle. 2016;15:2585–2592.
   PubMed Web of Science ®Google Scholar
• Kachalaki S, Baradaran B, Majidi J, et al. Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60). Biomed Pharmacother. 2015;75:100–104.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Goldar S. Silencing of high mobility group isoform IC (HMGI-C) enhances paclitaxel chemosensitivity in breast adenocarcinoma cells (MDA-MB-468). Adv Pharm Bull. 2016;6:171.
   PubMed Web of Science ®Google Scholar